Direct Comparison of B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP in a Large Population of Patients with Chronic and Symptomatic Heart Failure: The Valsartan Heart Failure (Val-HeFT) Data
Top Cited Papers
- 22 June 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 52 (8) , 1528-1538
- https://doi.org/10.1373/clinchem.2006.069575
Abstract
Background: The B-type or brain natriuretic peptides (BNP) and the amino-terminal probrain natriuretic peptide (NT-proBNP) are good markers of prognosis and diagnosis in chronic heart failure (HF). It is unclear, however, whether differences in their biological characteristics modify their clinical correlates and prognostic performance in HF. This work aimed to provide a direct comparison of the prognostic value of BNP and NT-proBNP in patients with chronic and stable HF. Methods: We measured BNP and NT-proBNP at baseline in 3916 patients enrolled in the Valsartan Heart Failure Trial. To identify the variables associated with both peptides, we conducted simple and multivariable linear regression analyses. We used Cox multivariable regression models to evaluate the independent prognostic value for all-cause mortality, mortality and morbidity, and hospitalization for HF. Prognostic performance was assessed by pairwise comparisons of the area under the curve of receiver-operator characteristic curves. Results: NT-proBNP and BNP had similar relationships with age, left ventrical ejection fraction, and internal diameter and creatinine clearance. Either peptide ranked as the first independent predictor of outcome after adjustment for major confounding clinical characteristics. ROC curves were almost superimposable for all-cause mortality (area under the curve (SE): BNP 0.665 (0.011) vs NT-proBNP 0.679 (0.011); P = 0.0734), but NT-proBNP was superior to BNP for predicting mortality and morbidity (P = 0.032) or hospitalization for HF (P = 0.0143). Overall sensitivity and specificity ranged from 0.590 to 0.696. Conclusions: The natriuretic peptides BNP and NT-proBNP showed subtle differences in their relation to clinical characteristics and prognostic performance in a large population of patients with chronic and stable HF. They were the most powerful independent markers of outcome in HF.Keywords
This publication has 35 references indexed in Scilit:
- Amino-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide in the General CommunityJournal of the American College of Cardiology, 2006
- Comparison of B-Type Natriuretic Peptides for Assessment of Cardiac Function and Prognosis in Stable Ischemic Heart DiseaseJournal of the American College of Cardiology, 2006
- Effect of Compensated Renal Dysfunction on Approved Heart Failure MarkersHypertension, 2005
- How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic reviewBMJ, 2005
- Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart diseaseClinica Chimica Acta; International Journal of Clinical Chemistry, 2004
- Diagnostic Accuracy and Prognostic Relevance of the Measurement of Cardiac Natriuretic Peptides: A ReviewClinical Chemistry, 2004
- Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breathJournal of the American College of Cardiology, 2003
- Surrogate end points in heart failureJournal of the American College of Cardiology, 2002
- Comparative Measurement of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide in Ambulatory Patients with Heart Failurecclm, 2002
- Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunctionClinica Chimica Acta; International Journal of Clinical Chemistry, 2001